Traffic Lights - Latest Updates

Last updated: 18/01/2018

Other updates on this site
Drug Name Classification Clinical Indication Comments
ACAMPROSATE (UPDATED) Amber Simple Alcohol dependence
ADALIMUMAB (NEW) Red Plaque psoriasis in children

In line with NICE TA 455

ADALIMUMAB (NEW) Red Non-infectious uveitis

In line with NICE TA 460

ALIMEMAZINE (UPDATED) Black

Current patients should be discussed with the prescribing specialist and not have treatment stopped abruptly without appropriate review.

APIXABAN (UPDATED) Amber Simple Treatment and secondary prevention of DVT and PE

In line with NICE TA 341

APREMILAST (Otezla®) (UPDATED) Red Psoriatic arthritis

In line with NICE TA 433

BASILIXIMAB (Simulect®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

BELATACEPT (Nulojix®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

BOTULINUM A TOXIN (Xeomin®) Red As per licence
CALCIPOTRIOL/BETAMETHASONE CUTANEOUS FOAM (Enstilar®) (UPDATED) Green Psoriasis vulgaris

Management of Psoriasis in Primary Care

CERTOLIZUMAB PEGOL (NEW) Red Psoriatic arthritis

In line with NICE TA 445

COLLAGENASE CLOSTRIDIUM HISTOLYCUM (NEW) Red Dupuytrens

In Line with NICE TA 459

CORNEAL EPITHELIAL CELLS (Ex vivo expanded autologous human) containing stem cells (Holoclar®) (NEW) Red Moderate-severe limbal stem cell deficiency after eye burns

In line with NICE TA 467

DACLIZUMAB (UPDATED) Red Relapsing forms of multiple sclerosis

In line with NICE TA 441

DEXAMETHASONE (NEW) Red Non-infectious uveitis

In line with NICE TA 460

DIMETHYL FUMARATE (NEW) Red Moderate to severe plaque psoriasis

In line with NICE TA 475

ELUXADOLINE (Truberzi®) (NEW) Red Irritable bowel syndrome with diarrhoea

In line with NICE TA 471

ETANERCEPT (NEW) Red Plaque psoriasis in children

In line with NICE TA 455

EVEROLIMUS (Certican®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

FLUTICASONE / AZELASTINE NASAL SPRAY (Dymista®) (UPDATED) Green Rhinitis

To be used in line with the Allergic Rhinitis Pathway

GLUCODRATE® (NEW) Amber Simple High Output Stoma (HOS)
GUSELKUMAB (Tremfya®) (NEW) Black Moderate to severe plaque psoriasis in adults
INSULIN GLARGINE (Toujeo® 300units per ml) (UPDATED) Green Diabetes mellitus in adults

UKMI – Product Safety Assessment Report
MUST BE PRESCRIBED BY BRAND NAME

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN (Thymoglobuline®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

RESLIZUMAB (NEW) Red Severe Eosinophilic Asthma

In line with NICE TA 479

RIVAROXABAN (UPDATED) Amber Simple Treatment and secondary prevention of DVT and PE

In line with  NICE TA 261  or  NICE TA 287

ROFLUMILAST (UPDATED) Amber Simple COPD

In line with NICE TA 461

SARILUMAB (NEW) Red Moderate to Severe Rheumatoid Arthritis

In line with NICE TA 485

TACROLIMUS SR (Envarsus®) (NEW) Red Prophylaxis of transplant rejection in adult kidney transplants
TOFACITINIB (NEW) Red Moderate to Severe Rheumatoid Arthritis

In line with NICE TA 480

USTEKINUMAB (NEW) Red Plaque psoriasis in children

In line with NICE TA 455

VALPROATE SEMISODIUM (Depakote®) (NEW) Amber Simple Mania in bipolar disorder

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more